ArticleEmerging infectious diseases2024
Concurrent Infection with Clade 2.3.4.4b Highly Pathogenic Avian Influenza H5N6 and H5N1 Viruses, South Korea, 2023.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Multiple introductions and spread of novel reassortant highly pathogenic avian influenza A (H5N1) clade 2.3.4.4b viruses via wild birds, South Korea, 2024-2025.Veterinary research · 2026Article
- Clade 2.3.4.4b H5N1 highly pathogenic avian influenza detected in wild bird feces, Eastern Mongolia, 2024.Journal of veterinary science · 2026Article
- Genomic and Clinicopathological Characterization of a Reassortant HPAI H5N1 (Clade 2.3.4.4b) in an Endangered Cinereous Vulture (Aegypius monachus) in South Korea, 2026.Transboundary and emerging diseases · 2026Article
- Pathogenicity in chickens and ducks of clade 2.3.4.4b H5N6 and H5N3 high pathogenicity avian influenza viruses in South Korea.Frontiers in veterinary science · 2026Article
- Emergence and Genetic Characteristics of H5N1, H5N6, and H5N3 Clade 2.3.4.4b High Pathogenicity Avian Influenza Viruses in South Korea During the 2023-2024 and 2024-2025 Winter Seasons.Transboundary and emerging diseases · 2026Article
- Epidemiology and pathobiology of H5Nx highly pathogenic avian influenza in South Korea (2003-2024): a comprehensive review.The veterinary quarterly · 2025Review
- Transmission Dynamics of Highly Pathogenic Avian Influenza A(H5N1) and A(H5N6) Viruses in Wild Birds, South Korea, 2023-2024.Emerging infectious diseases · 2025Article
- Protection of Ducks Against Highly Pathogenic H5Nx Avian Influenza Viruses by HA Cleavage Site Peptide Vaccine.Current microbiology · 2025Article
- Genetic insights into avian influenza resistance in Jeju Island chickens: the roles of Mx1 and oligoadenylate synthetase-like single nucleotide polymorphisms.Journal of animal science and technology · 2025Article
- Comparison of Gross Lesions in Poultry Naturally Infected With High Pathogenicity Avian Influenza H5N6 and H5N1 Viruses in South Korea, 2023-2025.Transboundary and emerging diseases · 2025Article
- Article
- Review
- Avian Influenza Virus A(H5Nx) and Prepandemic Candidate Vaccines: State of the Art.International journal of molecular sciences · 2024Review
- The Novel 2.3.4.4b H5N6 Highly Pathogenic Avian Influenza Viruses Isolated From Wild Birds in 2023 Posing a Potential Risk to Human Health.Transboundary and emerging diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highly pathogenic avian influenza H5N6 and H5N1 viruses of clade 2.3.4.4b were simultaneously introduced into South Korea at the end of 2023. An outbreak at a broiler duck farm consisted of concurrent infection by both viruses. Sharing genetic information and international surveillance of such viruses in wild birds and poultry is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.